Javascript must be enabled to continue!
e0540 Efficacy and safety of tirofiban-assisted Delayed PCI in Patients with ST-segment elavation myocardial infarction
View through CrossRef
Objective
To compare the outcomes of IIb/IIIa antagonist assisted PCI within 12–72 h of onset with that of selective PCI within 7–10 days in STEMI patients.
Methods
Totally, 80 patients were randomly allocated into the delayed PCI group (n=38) and the selective PCI group (n=42). In the delayed PCI group, PCI was performed within 12–72 h of onset. Tirofiban (10 μg/kg) was administered intravenously over 3 min immediately before PCI, and then was intravenously administered at 0.15 μg/kg/min during the procedure and for at least 36 h after PCI. In selective PCI group, PCI was performed within 7–10 days of onset. Blood platelet aggregation rate (PAR) was measured immediately before PCI (time 0) and at sequently different time points (30 min, 2 h, 6 h, 12 h, 48 h and 7 days). Final TIMI grade flow (TGF), corrected TIMI frame count (CTFC) and TIMI myocardial perfusion grade (TMPG) of the infarction related artery were recorded. Ultrasonic cardiography (1 week and 12 week after PCI) and raidonuclear ventricle imaging (RNVI) (1 week after PCI) parameters such as left ventricular peak ejection rate (LPER), left peak filling rate (LPFR), left ventricular time to peak ejection rate (LTPER) and left ventricular time to peak filling rate (LTPFR) were performed. Bleeding complications and major adverse cardiac events (MACE) were followed up for 3 months.
Results
In delayed PCI group, the cases with TGF 0–1 were significantly fewer before PCI, while the cases with TGF 3, TMPG 3 were more and CTFC was lower after PCI. The LPER, LPFR 1 week after PCI in delayed PCI group was higher and the LTPER, LTPFR were lower. LVEDD at 1 week and 3 months after PCI was all significantly smaller, while the LVEF was higher. There were no significant difference between the two groups regarding the incidence of hemorrhagic complications and MACEs.
Conclusion
Tirofiban facilitated delayed PCI for patients with STEMI of over 12 h of symptom onset is safe and effective.
Title: e0540 Efficacy and safety of tirofiban-assisted Delayed PCI in Patients with ST-segment elavation myocardial infarction
Description:
Objective
To compare the outcomes of IIb/IIIa antagonist assisted PCI within 12–72 h of onset with that of selective PCI within 7–10 days in STEMI patients.
Methods
Totally, 80 patients were randomly allocated into the delayed PCI group (n=38) and the selective PCI group (n=42).
In the delayed PCI group, PCI was performed within 12–72 h of onset.
Tirofiban (10 μg/kg) was administered intravenously over 3 min immediately before PCI, and then was intravenously administered at 0.
15 μg/kg/min during the procedure and for at least 36 h after PCI.
In selective PCI group, PCI was performed within 7–10 days of onset.
Blood platelet aggregation rate (PAR) was measured immediately before PCI (time 0) and at sequently different time points (30 min, 2 h, 6 h, 12 h, 48 h and 7 days).
Final TIMI grade flow (TGF), corrected TIMI frame count (CTFC) and TIMI myocardial perfusion grade (TMPG) of the infarction related artery were recorded.
Ultrasonic cardiography (1 week and 12 week after PCI) and raidonuclear ventricle imaging (RNVI) (1 week after PCI) parameters such as left ventricular peak ejection rate (LPER), left peak filling rate (LPFR), left ventricular time to peak ejection rate (LTPER) and left ventricular time to peak filling rate (LTPFR) were performed.
Bleeding complications and major adverse cardiac events (MACE) were followed up for 3 months.
Results
In delayed PCI group, the cases with TGF 0–1 were significantly fewer before PCI, while the cases with TGF 3, TMPG 3 were more and CTFC was lower after PCI.
The LPER, LPFR 1 week after PCI in delayed PCI group was higher and the LTPER, LTPFR were lower.
LVEDD at 1 week and 3 months after PCI was all significantly smaller, while the LVEF was higher.
There were no significant difference between the two groups regarding the incidence of hemorrhagic complications and MACEs.
Conclusion
Tirofiban facilitated delayed PCI for patients with STEMI of over 12 h of symptom onset is safe and effective.
Related Results
SAFETY AND EFFICACY OF THROMBOLYSIS FOLLOWED BY EARLY PERCUTANEOUS CORONARY INTERVENTION VIA TRANSRADIAL ARTERY APPROACH IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
SAFETY AND EFFICACY OF THROMBOLYSIS FOLLOWED BY EARLY PERCUTANEOUS CORONARY INTERVENTION VIA TRANSRADIAL ARTERY APPROACH IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
Objectives
This study was to investigate the safety and efficacy of thrombolysis followed by early PCI via transradial artery approach in patients with ST-segment...
Can Tirofiban Improve the Outcome of Patients With Acute Ischemic Stroke: A Propensity Score Matching Analysis
Can Tirofiban Improve the Outcome of Patients With Acute Ischemic Stroke: A Propensity Score Matching Analysis
Objective: To evaluate the efficacy and safety of tirofiban for patients with acute ischemic stroke (AIS), especially posterior circulation stroke (PCS).Methods: We enrolled consec...
e0484 The safety study of tirofiban in patients with STEMI during emergency PCI
e0484 The safety study of tirofiban in patients with STEMI during emergency PCI
Objective
To assess the safety of GP IIb/IIIa antagonists tirofiban in patients with ST elevation myocardial infarction (STEMI) during emergency Percutaneous Coro...
Predictors of Major Adverse Cardiac Events After Percutaneous Coronary Intervention in Sana’a City-Yemen (Single center study)
Predictors of Major Adverse Cardiac Events After Percutaneous Coronary Intervention in Sana’a City-Yemen (Single center study)
Background: Recently, many hospitals in Yemen have been started using Percutaneous Coronary Intervention (PCI) procedure for treatment coronary artery disease (CAD), including Dr. ...
Examining the Efficacy, Safety, and Future Prospects of Tirofiban in Managing Myocardial Infarction among Diabetic Patients
Examining the Efficacy, Safety, and Future Prospects of Tirofiban in Managing Myocardial Infarction among Diabetic Patients
Background:
Myocardial infarction (MI) is a leading cause of death worldwide, particularly
in patients with diabetes mellitus (DM). Tirofiban, a platelet GP IIb/IIIa receptor inhib...
CLINICAL STUDY OF INTRACORONARY INJECTION OF TIROFIBAN DURING DELAYED PCI IN TREATMENT OF ACUTE MYOCARDIAL INFARCTION
CLINICAL STUDY OF INTRACORONARY INJECTION OF TIROFIBAN DURING DELAYED PCI IN TREATMENT OF ACUTE MYOCARDIAL INFARCTION
Objectives
To evaluate the effect of intracoronary injection of tirofiban in treatment of acute myocardial infarction with recurring slow flow or no-reflow in the...
Safety and efficacy of early application of tirofiban in STEMI patients undergoing primary percutaneous coronary intervention
Safety and efficacy of early application of tirofiban in STEMI patients undergoing primary percutaneous coronary intervention
Objective
To explore the safety and efficacy of early application of tirofiban in STEMI patients undergoing primary percutaneous coronary intervention (PCI).
...
Possible effects and changes of myocardial injury markers in percutaneous coronary intervention
Possible effects and changes of myocardial injury markers in percutaneous coronary intervention
Objective
Percutaneous Coronary Intervention (PCI) is a technique of cardiac intervention treatment in revascularisation of coronary vessel. The use of PCI in pat...

